Drug__r.Drug_Code__c,Diagnosis__c
abatacept,Rheumatoid Arthritis
abatacept,Polyarticular Juvenile Idiopathic Arthritis (pJIA)
abatacept,Other
abobotulinum,cervical dystonia (spasmodic torticollis) in adults.
abobotulinum,focal spasticity
abobotulinum,Other
acetaminophen,Treatment of osteoarthritis only as monotherapy.
acetaminophen,Treatment osteoarthritis as an adjunct to NSAID therapy when additional pain relief is required.
acetaminophen,Other
COPDaclid,Diagnosis of chronic obstructive pulmonary disease (COPD)
COPDaclid,Other
COPDaclidform,Diagnosis of moderate to very severe COPD¹ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted. 
COPDaclidform,Other
adalimumab,Moderate to Severe Active Crohn's
adalimumab,Fistulizing Crohn's
adalimumab,Ulcerative Colitis
adalimumab,Rheumatoid Arthritis
adalimumab,Ankylosing Spondylitis
adalimumab,Psoriatic Arthritis
adalimumab,Polyarticular Juvenile Idiopathic Arthritis
adalimumab,Plaque Psoriasis
adalimumab,Hidradenitis Suppurativa
adalimumab,Other
alemtuzumab,As monotherapy for the treatment of relapsing-remitting multiple sclerosis
alenalen,clinical or radiographically documented fracture due to osteoporosis
alenalen,Glucocorticoid-induced osteoporosis in patients who are receiving or expected to receive the equivalent dose of 7.5 mg of prednisone per day or greater AND for 90 consecutive days or longer.
alenalen,Other
Pagetsalen,Diagnosis of Paget's disease
Pagetsalen,Other
alitretinoin,For the treatment of severe chronic hand eczema 
alitretinoin,Other
PAH1,For the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)
PAH1,Other
ADHDamph,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning."
ADHDamph,Other
DOACapix,Deep Vein Thrombosis (DVT)
DOACapix,Pulmonary Embolism (PE)
DOACapix,Non-valvular Atrial Fibrillation
DOACapix,Other
apomorphine,"For the acute, intermittent treatment of patients with advanced Parkinson's disease"
apomorphine,Other
aprepitant,For the prevention of acute and delayed nausea and vomiting due to highly-emetogenic cancer chemotherapy (HEC).
aprepitant,Other
aripip,Schizophrenia
aripip,Other psychosis (not dementia related)
aripip,Other
Maintenaarip,For management of manifestations of schizophrenia
Maintenaarip,For management of manifestations of related psychotic disorders (not dementia-related)
Maintenaarip,Other
aggrenox,For secondary prevention of cerebrovascular occlusion and embolization in patients who have experienced recurrent TIA OR stroke while receiving ASA alone
aggrenox,Other
asenapine,Diagnosis of Bipolar I Disorder
asenapine,Other
ADHDatom,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning."
ADHDatom,Other
azet,For the cyclic treatment of chronic Pseudomonas aeruginosa infections in patients with moderate to severe cystic fibrosis
azet,A deteriorating clinical condition despite treatment with inhaled tobramycin
azet,Other
baclofen,Severe spasticity due to multiple sclerosis
baclofen,Severe spasticity due to spinal cord injury
baclofen,Other
ACEIdena,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIdena,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIdena,Other
benralizumab,severe eosinophilic asthma
benralizumab,other
benzydamine,"For the treatment of mucositis, ulcerative complications of chemotherapy"
benzydamine,Immunocompromised patients at risk of mucosal breakdown.
PAH2,"As monotherapy, for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)"
PAH2,"As monotherapy, for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH)"
brex,Schizophrenia
brex,Other psychosis (not dementia related)
brex,Other
budenema,Ulcerative Colitis
budenema,Other
budcaps,Crohn's disease
budcaps,Other
nebulesbude,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece
nebulesbude,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination
nebulesbude,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily
nebulesbude,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber.
nebulesbude,Other
bupre inj,Patient is an adult and have been induced and clinically stabilized on an equivalent of 8 mg to 24 mg of transmucosal buprenorphine-naloxone for a minimum of seven days
bupre inj,Exceptional coverage consideration
bupropiondepression,Depression
bupropiondepression,Other
ARBcand,Patient has experienced intractable cough
ARBcand,Patient has experienced angioedema
ARBcand,Other
ACEIcapt,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIcapt,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIcapt,Other
duodopa,For the management of severe cases of advanced idiopathic Parkinson's Disease 
duodopa,Patient experiences severe disability despite having tried frequent dosing of levodopa
carv,For treatment of stable symptomatic congestive heart failure:
carv,Concurrent therapy with an Angiotensin Converting Enzyme inhibitor (ACE-I)
carv,Unable to take ACE-I (provide details):
celecox,Rheumatoid Arthritis
celecox,Psoriatic Arthritis
celecox,Ankylosing Spondylitis
celecox,Gout 
celecox,Lupus
celecox,"Treatment failure on optimal doses of, or intolerance to, both ibuprofen and naproxen."
celecox,Other
certo,Rheumatoid Arthritis
certo,Ankylosing Spondylitis
certo,Psoriatic Arthritis
certo,Other
chlorambucil,Vasculitis
chlorambucil,Lupus
chlorambucil,Other
chloroquine,Treatment of extraintestinal amebiasis
chloroquine,Rheumatoid Arthritis
chloroquine,Lupus
chloroquine,Other
antifungalciclo,Diagnosis of a fungal infection of the lower extremities - diabetes
antifungalciclo,Diagnosis of a fungal infection of the lower extremities - circulatory condition
antifungalciclo,Diagnosis of a fungal infection of the lower extremities - other
antifungalciclo,Other
ACEIcila,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIcila,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIcila,Other
H2Bcime,"Treatment failure on prescription dose of, or intolerance to, ranitidine"
H2Bcime,Other
ciproophthcipr,Failure or intolerance to first-line agents (e.g. aminoglycosides)
ciproophthcipr,Other
antifungalclio,Diagnosis of a fungal infection of the lower extremities - diabetes
antifungalclio,Diagnosis of a fungal infection of the lower extremities - circulatory condition
antifungalclio,Diagnosis of a fungal infection of the lower extremities - other
antifungalclio,Other
clobazam,Treatment of anxiety
clobazam,Other
antifungalclot,Diagnosis of a fungal infection of the lower extremities - diabetes
antifungalclot,Diagnosis of a fungal infection of the lower extremities - circulatory condition
antifungalclot,Diagnosis of a fungal infection of the lower extremities - other
antifungalclot,Other
codeine,Diagnosis of cancer
codeine,For pain management in a specified chronic pain diagnosis
codeine,Other
cyclosporin,Rheumatoid Arthritis
cyclosporin,Severe ocular inflammatory disease
cyclosporin,Extensive psoriasis involving at least 25% of body surface or having psoriasis area and severity index of at least 12
cyclosporin,Topical therapy with corticosteroids
cyclosporin,Ultraviolet-B light or oral or topical methoxsalen plus ultraviolet-A ligh
cyclosporin,UVB/UVA light therapy is not available
cyclosporin,Psoriasis of the palms and/or soles severe enough to interfere with daily living or work
cyclosporin,Treatment failure on topical corticosteroid
cyclosporin,Nephrotic syndrome
cyclosporin,Other
cyprooral,Indication of need to reduce aggressive sexual drive
cyprooral,Other
cyproinj,Indication of need to reduce aggressive sexual drive
cyproinj,Other
afibdaba,Patient has a diagnosis of non-valvular atrial fibrillation
afibdaba,Other
dalteparin,Treatment of venous thromboembolism
dalteparin,Treatment of venous thromboembolism associated with cancer
dalteparin,Prophylaxis of venous thromboembolism
dalteparin,Other
defersirox,Congenital disease
defersirox,Acquired disease
defersirox,Other
deferprox ,Congenital disease
deferprox ,Acquired disease
deferprox ,Other
denosprol,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - immune-mediated hypersensitivity reaction to oral bisphosphonates
denosprol,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia
denosprol,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - other
denosprol,Other
desmopressin,Treatment of diabetes insipidus
desmopressin,Other
diclomiso,Rheumatoid Arthritis
diclomiso,Psoriatic Arthritis
diclomiso,Ankylosing Spondylitis
diclomiso,Gout 
diclomiso,Lupus
diclomiso,Other
dienogest,For the management of pelvic pain associated with endometriosis
dienogest,Experienced treatment failure on combined hormonal contraceptives
dienogest,Unable to use combined hormonal contraceptives
dienogest,Other
NSAIDdiflu,Rheumatoid Arthritis
NSAIDdiflu,Psoriatic Arthritis
NSAIDdiflu,Ankylosing Spondylitis
NSAIDdiflu,Gout
NSAIDdiflu,Lupus
NSAIDdiflu,Other
dimethylfumarate,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial
dimethylfumarate,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal
dimethylfumarate,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch
LBMdiph,For the treatment of diarrhea due to a specified chronic illness
LBMdiph,Other
ADTIdone,"Initial - mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease"
ADTIdone,"Renewal -  mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease"
ADTIdone,Other
dorzolamide,Diagnosis of ocular hypertension and open-angle glaucoma in patients with a demonstrated allergy to preservative
dorzolamide,Other
dronedarone,"For long-term rhythm control of atrial fibrillation (AF) who successfully achieved rhythm control on amiodarone, but who have developed intolerable adverse effects to amiodarone (NOT including liver adverse effects)"
dronedarone,Other
duloxetine,For the treatment of neuropathic pain
duloxetine,Other
BPHDUTA,Diagnosis of benign prostatic hyperplasia (BPH)
BPHDUTA,other
edaravone,Initial Request - Diagnosis of probable amyotrophic lateral sclerosis (ALS) or definite ALS
edaravone,Renewal Request 
edaravone,Other
zepatier,Genotype 1a - treatment-naïve: 12 weeks
zepatier,Genotype 1b - treatment-naïve: 12 weeks
zepatier,Genotype 1a or 1b - treatment-experienced (prior relapsers): 12 weeks
zepatier,Genotype 1b - treatment-experienced (prior on-treatment virologic failures): 12 weeks
zepatier,Genotype 1a - treatment-experienced (prior on-treatment virologic failures): 16 weeks
zepatier,Genotype 4 - treatment-naïve: 12 weeks
zepatier,Genotype 4 - treatment-experienced (prior relapsers): 12 weeks
zepatier,Genotype 4 - treatment-experienced (prior on-treatment virologic failures) with RBV: 16 weeks
SGLT2,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea
SGLT2,Type 2 diabetes - Dual therapy of metformin and an insulin
SGLT2,Type 2 diabetes - trial of one agent
SGLT2,Other
ACEIenap,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIenap,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIenap,other
enoxaparin,Treatment of venous thromboembolism
enoxaparin,Prophylaxis of venous thromboembolism
enoxaparin,Other
entacapone,Parkinson's Disease - As adjunct therapy for patients with an inadequate response after alterations of levodopa/carbidopa doses.
entacapone,Other
entacapone,Other
entecavir,Chronic Hepatitis B
entecavir,Other
epoprostenol,"As monotherapy, for the treatment of WHO/NYHA functional class IV PAH and inadequate response to non-prostanoid therapies"
epoprostenol,"As monotherapy, for the treatment of WHO/NYHA functional class IV PAH and contraindication to the non-prostanoid therapies"
epoprostenol,Other
ARBepro,Patient has experienced intractable cough on an Angiotensin Converting Enzyme Inhibitor (ACE-I): ALL reference ARBs must have been unsucessfully tried
ARBepro,Patient has experienced angioedema on an Angiotensin Converting Enzyme Inhibitor (ACE-I): ALL reference ARBs must have been unsucessfully tried
ARBepro,Other
eslicarbazepine,Adjunctive therapy for partial-onset seizures in adults after other medications have been tried without success
eslicarbazepine,Other 
2PPIesom,Gastroesophageal reflux disease (GERD)
2PPIesom,Reflux esophagitis
2PPIesom,Duodenal ulcer
2PPIesom,Gastric ulcer
2PPIesom,Barrett's esophagus
2PPIesom,Zollinger-Ellison syndrome
2PPIesom,"Connective tissue disease (e.g., lupus, scleroderma, crest),"
2PPIesom,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)"
2PPIesom,Other
estraderm,For indications of menopausal and post-menopausal symptoms - Extreme intolerance to oral preparations
estraderm,For indications of menopausal and post-menopausal symptoms - Diagnosis of severe liver disease
estraderm,For indications of menopausal and post-menopausal symptoms - other
estraderm,Other
etanbiosim,Rheumatoid Arthritis
etanbiosim,Ankylosing Spondylitis
etanbiosim,Plaque Psoriasis
etanbiosim,Psoriatic Arthritis
etanbiosim,Other
evo,"Initial Request - Diagnosis of ""definite"" or ""probable"" Heterozygous Familial Hypercholesterolemia (HeFH) - Simon Broome criteria"
evo,"Initial Request - Diagnosis of ""definite"" or ""probable"" Heterozygous Familial Hypercholesterolemia (HeFH) - Dutch Lipid Network criteria"
evo,"Initial Request - Diagnosis of ""definite"" or ""probable"" Heterozygous Familial Hypercholesterolemia (HeFH) - Genetic testing"
evo,Renewal Request - LDL-C is reduced by at least 40% from the LDL prior to treatment with evolocumab 
ezetimibe,Patient has a diagnosis of hypercholesterolemia.
ezetimibe,Other
H2Bfamo,"Treatment failure on prescription dose of, or intolerance to, ranitidine"
H2Bfamo,Other
febuxostat,For the reduction of serum uric acid levels in patients with gout who demonstrate an immune-mediated hypersensitivity reaction to allopurinol
febuxostat,Other
CCBfelo,"Treatment failure on optimal dose of, or intolerance to, amlodipine"
CCBfelo,Complex patient requiring medications for co-existing chronic condition(s)
CCBfelo,Other
fent patch,Diagnosis of cancer
fent patch,For pain management in a specified chronic pain diagnosis
fent patch,Other
fidaxomicin,treatment of C. Difficile - documented allergy 
fidaxomicin,treatment of C. Difficile - severe intolerance to oral vancomycin
fidaxomicin,treatment of C. Difficile - failure of oral vancomycin AND when retreatment with vancomycin is not an option AND when the patient is at high risk of hospitalization
fidaxomicin,Other
filgrastim,Post-BMT to stimulate bone marrow engraftment
filgrastim,Post-BMT for rescue of failure to engraft
filgrastim,Cancer patients undergoing peripheral blood progenitor cell (PBPC) collection and therapy
filgrastim,For rescue of prolonged febrile neutropenia following chemotherapy
filgrastim,For PRIMARY prophylaxis of febrile neutropenia in cancer patients receiving potentially CURATIVE myelosuppressive chemotherapy regimens
filgrastim,For SECONDARY prophylaxis of febrile neutropenia in cancer patients receiving potentially CURATIVE myelosuppressive chemotherapy
filgrastim,Chronic benign cyclical neutropenia
filgrastim,Myelodysplastic disorders or aplastic anemia awaiting bone marrow transplantation
BPHFINA,Diagnosis of benign prostatic hyperplasia (BPH)
BPHFINA,other
fingolimod,As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis
fingolimod,other
fluconsolids,Immunocompromised patient
fluconsolids,Exceptions on an individual basis for fungal infections resistant to first-line medications.
fluconsolids,Other
NSAIDflur,Rheumatoid Arthritis
NSAIDflur,Psoriatic Arthritis
NSAIDflur,Ankylosing Spondylitis
NSAIDflur,Diagnosis of gout
NSAIDflur,Lupus
NSAIDflur,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
NSAIDflur,Other
LABAflutsalm,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.
LABAflutsalm,Other
COPDflutsalm,Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted
COPDflutsalm,Other
COPDflutumecvila,Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted
COPDflutumecvila,Other
LABAflutvila,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.
LABAflutvila,Other
COPDflutvila,Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted
COPDflutvila,Other
statinsfluv,Results of trial to atorvastatin - Treatment failure
statinsfluv,Results of trial to atorvastatin - Intolerance
statinsfluv,Results of trial to atorvastatin - Other
statinsfluv,Results of trial to rosuvastatin - Treatment failure
statinsfluv,Results of trial to rosuvastatin - Intolerance
statinsfluv,Results of trial to rosuvastatin - Other
statinsfluv,Other
LABAform,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.
LABAform,Other
LABAformbude,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.
LABAformbude,Other
LABAformmom,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.
LABAformmom,Other
ACEIfosi,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIfosi,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIfosi,Other
gabapentin,Diagnosis of Bipolar Disorder
gabapentin,Other
ADTIgala,"Initial - mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease"
ADTIgala,"Renewal -  mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease"
ADTIgala,Other
glatiramer,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial
glatiramer,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal
glatiramer,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch
maviret,Genotype 1 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks
maviret,Genotype 1 - Treatment-experienced¹ with no cirrhosis: for 8 weeks
maviret,Genotype 1 - Treatment-experienced¹ with compensated cirrhosis²: 12 weeks
maviret,"Genotype 1 - Previously treated³ with an NS3/4A protease inhibitor-containing regimen, but NS5A inhibitor treatment-naive: 12 weeks."
maviret,"Genotype 1 - Previously treated⁴ with an NS5A inhibitor-containing regimen, but NS3/4A protease inhibitor treatment-naive: 16 weeks"
maviret,genotype 2 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks
maviret,Genotype 2 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.
maviret,Genotype 2 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.
maviret,genotype 3 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks
maviret,Genotype 3 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.
maviret,Genotype 3 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.
maviret,genotype 4 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks
maviret,Genotype 4 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.
maviret,Genotype 4 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.
maviret,genotype 5 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks
maviret,Genotype 5 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.
maviret,Genotype 5 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.
maviret,genotype 6 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks
maviret,Genotype 6 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.
maviret,Genotype 6 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.
maviret,heart transplant recipient
maviret,kidnet transplant recipient
gliclazide,"Treatment failure or intolerance to at least one other sulfonylurea drug (e.g., glyburide, tolbutamide) at adequate doses."
gliclazide,Other
COPDglyc,Diagnosis of chronic obstructive pulmonary disease (COPD) AND failureof both tiotropium and umeclidinium
COPDglyc,Other
golim,Rheumatoid Arthritis
golim,Ankylosing Spondylitis
golim,Psoriatic Arthritis
golim,Other
goserelin,Patient has a diagnosis of endometriosis
goserelin,Other
antiemeticgran,Prescribed for the prevention and treatment of nausea and vomiting associated with chemotherapy
antiemeticgran,Other
hydromorph50inj,"Relief of severe pain in patients who require subcutaneously, intravenously or intramuscularly administered opioids in doses or concentrations higher than those usually needed"
hydromorph50inj,Other
hydromorphSR,Pain management in a specified chronic pain (including cancer pain) diagnosis AND regular release dosage forms of hydromorphone
hydromorphSR,Pain management in a specified chronic pain (including cancer pain) diagnosis AND sustained release preparations of morphine
hydromorphSR,Other
hydroxyurea,Patient has a diagnosis of pustular psoriasis 
hydroxyurea,Other
hydroxyzine,For the treatment of anxiety
hydroxyzine,Other
icat,Initial Request - For the treatment of acute attacks of hereditary angioedema (HAE) - type I
icat,Initial Request - For the treatment of acute attacks of hereditary angioedema (HAE) - type II
icat,Initial Request - For the treatment of acute attacks of hereditary angioedema (HAE) - other
icat,Renewal Request - Patient is limited to a single dose for self-administration per attack
incobot,For the treatment of blepharospasm
incobot,For the treatment of cervical dystonia of a predominantly rotational form (Spasmodic Torticollis)
incobot,For the treatment of post-stroke spasticity of the upper limb
incobot,Other
COPDinda,Diagnosis of COPD with a post-bronchodilator FEV1/FVC < 0.70 AND contraindication or intolerance to a long-acting muscarinic receptor antagonist (LAMAs)
COPDinda,Other
COPDindaglyc,Diagnosis of moderate to very severe COPD¹ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted AND inadequate response after minimum of 6 month trial of either LAMA or LABA
COPDindaglyc,Other
indapamide,Treatment failure or intolerance to a thiazide diuretic
indapamide,Other
NSAIDindo,Rheumatoid Arthritis
NSAIDindo,Psoriatic Arthritis
NSAIDindo,Ankylosing Spondylitis
NSAIDindo,Gout 
NSAIDindo,Lupus
NSAIDindo,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
NSAIDindo,Other
inflix,Moderate to Severe Active Crohn's
inflix,Fistulizing Crohns
inflix,Ulcerative Colitis
inflix,Rheumatoid Arthritis
inflix,Ankylosing Spondylitis
inflix,Psoriatic Arthritis
inflix,Plaque Psoriasis
inflix,Other
Lainsulindete,Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced unexplained nocturnal hypoglycemia at least once a month despite optimal management
Lainsulindete,"Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced or continues to experience severe, systemic or local allergic reaction to existing insulin treatment"
Lainsulindete,Patient has a contraindication to NPH insulin
Lainsulindete,Other
LAinsulinbasa,Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced unexplained nocturnal hypoglycemia at least once a month despite optimal management
LAinsulinbasa,"Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced or continues to experience severe, systemic or local allergic reaction to existing insulin treatment"
LAinsulinbasa,Patient has a contraindication to NPH insulin
LAinsulinbasa,Other
interferonA,"Chronic Hepatitis B, non-cirrhosis"
interferonA,Other
Avonex,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial
Avonex,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal
Avonex,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch
Rebif,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial
Rebif,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal
Rebif,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch
interferonB1B,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial
interferonB1B,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal
interferonB1B,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch
interferonB1B,As monotherapy for secondary progressive multiple sclerosis (SPMS) - initial
interferonB1B,As monotherapy for secondary progressive multiple sclerosis (SPMS) - renewal
interferonB1B,As monotherapy for secondary progressive multiple sclerosis (SPMS) - switch
nebulesipra,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece
nebulesipra,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices
nebulesipra,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily
nebulesipra,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber
nebulesipra,Other
nebulesiprasalb,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece
nebulesiprasalb,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices
nebulesiprasalb,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily
nebulesiprasalb,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber
nebulesiprasalb,Other
ARBirbe,Patient has experienced intractable cough
ARBirbe,Patient has experienced angioedema
ARBirbe,Other
isavuconazole,For the treatment of Invasive Mucormycosis (IM) in adults when prescribed by infectious disease specialist and if a patient is established on isavuconazole in hospital
isavuconazole,Other
ismn,Diagnosis of unstable angina
ismn,Experienced treatment failure on optimal dose of isosorbide dinitrate (ISDN)
ismn,Experienced intolerance to isosorbide dinitrate (ISDN)
ismn,Other
itraconazole,Immunocompromised patient
itraconazole,Pulse treatment for severe onychomycosis with functional disability
itraconazole,Other
ivabradine,Patient has stable heart failure with New York Heart Association Class II or III symptoms
ivabradine,"NYHA class II or III symptoms that have persisted despite at least four weeks of treatment at the optimum stable dose of a B-blocker, an aldosterone antagonist AND an ACEI or an ARB"
ivabradine,Other
ixekiz,Plaque Psoriasis
ixekiz,Other
antifungalketo,Diagnosis of a fungal infection of the lower extremities - diabetes
antifungalketo,Diagnosis of a fungal infection of the lower extremities - circulatory condition
antifungalketo,Diagnosis of a fungal infection of the lower extremities - other
antifungalketo,Other
NSAIDketo,Rheumatoid Arthritis
NSAIDketo,Psoriatic Arthritis
NSAIDketo,Ankylosing Spondylitis
NSAIDketo,Gout
NSAIDketo,Lupus
NSAIDketo,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
NSAIDketo,Other
NSAIDketoSR,Rheumatoid Arthritis
NSAIDketoSR,Psoriatic Arthritis
NSAIDketoSR,Ankylosing Spondylitis
NSAIDketoSR,Gout
NSAIDketoSR,Lupus
NSAIDketoSR,"Treatment failure on optimal dose, or intolerance to, at least one of enteric-coated ASA, ibuprofen, or naproxen"
NSAIDketoSR,Other
lacolaco,For adjunctive therapy (to be used in combination with at least ONE other anti-epileptic drug) for partial-onset seizures
lacolaco,Other
lactulose,Treatment of portal systemic encephalopathy
lactulose,Treatment of liver failure
lactulose,Other
lamivudine,Chronic Hepatitis B
lamivudine,Other - Hepatitis B reactivation prophylaxis while on immunosuppressants
lamivudine,Other
2PPIlans,Gastroesophageal reflux disease (GERD)
2PPIlans,Reflux esophagitis
2PPIlans,Duodenal ulcer
2PPIlans,Gastric ulcer
2PPIlans,Barrett's esophagus
2PPIlans,Zollinger-Ellison syndrome
2PPIlans,"Connective tissue disease (e.g., lupus, scleroderma, crest),"
2PPIlans,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)"
2PPIlans,Other
harvoni,"Genotype 1 - Treatment-naive, mono-HCV infected, fibrosis stage < F3 and HCV RNA < 6 million IU/mL (only considered for non-cirrhotic patients): 8 weeks. "
harvoni,Genotype 1 - Treatment-naive with no cirrhosis (including advanced fibrosis stage ≥ 3) or with compensated cirrhosis¹: 12 weeks.
harvoni,Genotype 1 - Treatment-experienced² with no cirrhosis:  12 weeks.
harvoni,"Genotype 1 - HIV/HCV-1 co-infected, treatment-naive or treatment-experienced² with no cirrhosis or with compensated cirrhosis¹: 12 weeks."
harvoni,Genotype 1 - Treatment-experienced² with compensated cirrhosis¹: 24 weeks.
harvoni,Genotype 1 - Treatment-naive or treatment-experienced² with decompensated cirrhosis³: (with RBV) for 12 weeks.
harvoni,"Genotype 1 - Liver transplant recipients, treatment-naive or treatment-experienced² with no cirrhosis or with compensated cirrhosis¹:  (with RBV) for 12 weeks."
leflunomide,Rheumatoid Arthritis
leflunomide,Other
leuprolide,Diagnosis of precocious puberty
leuprolide,Diagnosis of endometriosis
leuprolide,Diagnosis indicating need to reduce sexual drive
leuprolide,Other
levetiracetam,Diagnosis of epilepsy
levetiracetam,Other
DPP4lina,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea
DPP4lina,Type 2 diabetes - Dual therapy of metformin and an insulin
DPP4lina,Type 2 diabetes - trial of one agent
DPP4lina,Other
linezolid,Treatment of vancomycin resistant enterococcus (VRE) infections
linezolid,Treatment of methicillin-resistant staphylococcus aureus (MRSA) in patients who are unresponsvie to or intolerant of injectable vancomycin
linezolid,Other
ADHDlisd,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - methylphenidate IR/SR"
ADHDlisd,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - dextroamphetamine IR/SR"
ADHDlisd,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - other"
ADHDlisd,Other
ACEIliso,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIliso,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIliso,Other
LBMlope,For the treatment of diarrhea due to a specified chronic illness
LBMlope,Other
ARBlosa,Patient has experienced intractable cough
ARBlosa,Patient has experienced angioedema
ARBlosa,Other
statinslova,"Treatment failure on optimal doses of, OR specified intolerance to BOTH reference drugs: atorvastatin AND rosuvastatin"
statinslova,Other
meloxicam,Rheumatoid Arthritis
meloxicam,Psoriatic Arthritis
meloxicam,Ankylosing Spondylitis
meloxicam,Gout
meloxicam,Lupus
meloxicam,"Treatment failure on optimal doses of, or intolerance to, both ibuprofen and naproxen"
meloxicam,Other
mepolizumab,severe eosinophilic asthma
mepolizumab,other
mercaptopurine,Ulcerative Colitis
mercaptopurine,Autoimmune hepatitis
mercaptopurine,Inflammatory bowel disease
mercaptopurine,Crohn's disease
mercaptopurine,Other
methotrexatePFsyringe,"Treatment of rheumatoid arthritis, when the patient demonstrates failure on or intolerance to oral methotrexate"
methotrexatePFsyringe,Other
methotrexateVial,"Treatment of rheumatoid arthritis, when the patient demonstrates failure on or intolerance to oral methotrexate"
methotrexateVial,Other
ADHDmeth,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - methylphenidate IR/SR"
ADHDmeth,"Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) with hyperactivity, impulsivity, or inattention that interferes with functioning and - dextroamphetamine IR/SR"
ADHDmeth,"Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) with hyperactivity, impulsivity, or inattention that interferes with functioning and - other"
ADHDmeth,Other
antifungalmico,Diagnosis of a fungal infection of the lower extremities - diabetes
antifungalmico,Diagnosis of a fungal infection of the lower extremities - circulatory condition
antifungalmico,Diagnosis of a fungal infection of the lower extremities - other
antifungalmico,Other
modafinil,Treatment of narcolepsy
modafinil,Other
mometNS,Diagnosis of allergic rhinitis in child 3-11 years old
mometNS,Other
mmf,Autoimmune hepatitis
mmf,Bullous pemphigold
mmf,Other
nabumetone,Rheumatoid Arthritis
nabumetone,Psoriatic Arthritis
nabumetone,Ankylosing Spondylitis
nabumetone,Gout
nabumetone,Lupus
nabumetone,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
nabumetone,Other
nadroparin,Treatment of venous thromboembolism
nadroparin,Prophylaxis of venous thromboembolism
nadroparin,Other
naproEC,Rheumatoid Arthritis
naproEC,Psoriatic Arthritis
naproEC,Ankylosing Spondylitis
naproEC,Gout
naproEC,Lupus
naproEC,"Treatment failure on optimal dose, or intolerance to, at least one of enteric-coated ASA, ibuprofen, or naproxen"
naproEC,Other
natalizumab,As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis
natalizumab,other
netupitant,For the prevention of acute and delayed nausea and vomiting due to highly-emetogenic cancer chemotherapy in combination with dexamethasone
netupitant,Other
CCBnife,"Treatment failure on optimal dose of, or intolerance to, amlodipine"
CCBnife,Complex patient requiring medications for co-existing chronic condition(s)
CCBnife,Other
nintedanib,Initial - For the treatment of adult patients who have a diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF)
nintedanib,First renewal - idiopathic pulmonary fibrosis (IPF)
nintedanib,Second and subsequent renewal - idiopathic pulmonary fibrosis (IPF)
nintedanib,Other
nitisinone,hereditary tyrosinemia type 1 (HT-1) - for patients identified through newborn screening
nitisinone,hereditary tyrosinemia type 1 (HT-1) - for patients identified through prenatal genetic testing
H2Bniza,"Treatment failure on prescription dose of, or intolerance to, ranitidine"
H2Bniza,Other
OBE,For treatment of adult patient with confirmed diagnosis of primary billary cholangitis (PBC) - positive antimitochondrial antibodies
OBE,For treatment of adult patient with confirmed diagnosis of primary billary cholangitis (PBC) - liver biopsy results consistent with PBC
OBE,Obeticolic acid will be used in combination with ursodeoxycholic acid (UDCA)
OBE,Obeticholic acid will be used as monotherapy in patient
OBE,Other
ocrelizumab,As treatment for Early Primary Progressive Multiple Sclerosis (PPMS)
ocrelizumab,Other
cipro ophthoflox,Failure or intolerance to first-line agents (e.g. aminoglycosides)
cipro ophthoflox,Other
olan,Diagnosis of Schizophrenia AND treatment failure or intolerance to at least one other specified anti-psychotic agent
olan,Diagnosis of other psychosis (not dementia related) AND treatment failure or intolerance to at least one other specified anti-psychotic agent
olan,"Diagnosis of Bipolar I disorder AND treatment failure or intolerance to lithium, carbamazepine or divalproex sodium AND treatment failure or intolerance to at least one other specified anti-psychotic agent"
olan,Other
ARBolme,Patient has experienced intractable cough
ARBolme,Patient has experienced angioedema
ARBolme,Other
2PPIomep,Gastroesophageal reflux disease (GERD)
2PPIomep,Reflux esophagitis
2PPIomep,Duodenal ulcer
2PPIomep,Gastric ulcer
2PPIomep,Barrett's esophagus
2PPIomep,Zollinger-Ellison syndrome
2PPIomep,"Connective tissue disease (e.g., lupus, scleroderma, crest),"
2PPIomep,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)"
2PPIomep,Other
onabot,Treatment of spasmodic torticollis
onabot,Treatment of blepharospasm.
onabot,Treatment of strabismus
onabot,Treatment of equinus foot deformity due to spasticity in pediatric Cerebral Palsy patients 2 years of age or older.
onabot,"Treatment of focal spasticity, including the treatment of upper limb spasticity associated with stroke in adults."
onabot,"Treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) associated with multiple sclerosis or subcervical spinal cord injury,"
onabot,Treatment of overactive bladder (OAB) in adult patients
onabot,Other
antiemeticonda,Prevention and treatment of nausea and vomiting associated with chemotherapy
antiemeticonda,Other
Maintenapalisust,For management of manifestations of schizophrenia
Maintenapalisust,"For management of manifestations of related psychotic disorders (not dementia-related) - have tried oral aripiprazole, risperidone, or paliperidone PLUS at least one other antipsychotic agent AND continues to be inadequately controlled"
Maintenapalisust,For management of manifestations of related psychotic disorders (not dementia-related) - are currently receiving a conventional depot antispychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia
Maintenapalisust,For management of manifestations of related psychotic disorders (not dementia-related) - with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations
Maintenapalisust,Other
Maintenapalitrin,For management of manifestations of schizophrenia
Maintenapalitrin,"For management of manifestations of related psychotic disorders (not dementia-related) - have tried oral aripiprazole, risperidone, or paliperidone PLUS at least one other antipsychotic agent AND continues to be inadequately controlled"
Maintenapalitrin,For management of manifestations of related psychotic disorders (not dementia-related) - are currently receiving a conventional depot antispychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia
Maintenapalitrin,For management of manifestations of related psychotic disorders (not dementia-related) - with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations
Maintenapalitrin,Other
pamidronate,Diagnosis indicating bone metastases associated with cancer (except breast cancer)
pamidronate,Other
1PPIpant,Gastroesophageal reflux disease (GERD)
1PPIpant,Reflux esophagitis
1PPIpant,Duodenal ulcer
1PPIpant,Gastric ulcer
1PPIpant,Barrett's esophagus
1PPIpant,Zollinger-Ellison syndrome
1PPIpant,"Connective tissue disease (e.g., lupus, scleroderma, crest),"
1PPIpant,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)"
1PPIpant,Other
2PPIpant,Gastroesophageal reflux disease (GERD)
2PPIpant,Reflux esophagitis
2PPIpant,Duodenal ulcer
2PPIpant,Gastric ulcer
2PPIpant,Barrett's esophagus
2PPIpant,Zollinger-Ellison syndrome
2PPIpant,"Connective tissue disease (e.g., lupus, scleroderma, crest),"
2PPIpant,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)"
2PPIpant,Other
2PPIpant,Previously tried Proton Pump Inhibitors - rabeprazole AND pantoprazole magnesium
2PPIpant,Patient has contraindications to one or more 1st line PPIs
pentazocine,For pain management in a specified pain diagnosis
pentazocine,Patient has experienced treatment failure or intolerance to at least two identified opioids
pentazocine,Other
lacopera,For adjunctive therapy (to be used in combination with at least ONE other anti-epileptic drug) for partial-onset seizures
lacopera,At least four other anti-epileptic medications have been tried without success
lacopera,Other
ACEIperi,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIperi,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIperi,Other
pimecro,Diagnosis of eczema - refractory to three months of potent topical corticosteroid therapy
pimecro,Diagnosis of eczema - intolerant to topical corticosteroid treatment
pimecro,Other
TZDpio,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea
TZDpio,Type 2 diabetes - Dual therapy of metformin and an insulin
TZDpio,Type 2 diabetes - trial of one agent
TZDpio,Other
pirfenidone,Initial - For the treatment of adult patients who have a diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF)
pirfenidone,First renewal - idiopathic pulmonary fibrosis (IPF)
pirfenidone,Second and subsequent renewal - idiopathic pulmonary fibrosis (IPF)
pirfenidone,Other
piroxicam,Rheumatoid Arthritis
piroxicam,Psoriatic Arthritis
piroxicam,Ankylosing Spondylitis
piroxicam,Gout
piroxicam,Lupus
piroxicam,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
piroxicam,Other
prami,For the treatment of idiopathic Parkinson's disease - receiving treatment with levodopa and requires additional adjunctive therapy
prami,For the treatment of idiopathic Parkinson's disease - cannot tolerate or has contraindications to levodopa
prami,For the treatment of idiopathic Parkinson's disease - other
prami,Other
statinsprav,"Treatment failure on optimal doses of, OR specified intolerance to BOTH reference drugs: atorvastatin AND rosuvastatin"
statinsprav,Other
propranolol,initial - proliferating infantilei hemangioma requiring systemic therapy
propranolol,renewal - proliferating infantilei hemangioma requiring systemic therapy
prostaglandin,Erectile dysfunction that occurs as a result of vascular or neurological damage that precludes adequate filling of the sinusoidal spaces
prostaglandin,Other
ACEIquin,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEIquin,Complex patient requiring medication(s) for co-existing chronic condition(s)
ACEIquin,Other
1PPIrabe,Gastroesophageal reflux disease (GERD)
1PPIrabe,Reflux esophagitis
1PPIrabe,Duodenal ulcer
1PPIrabe,Gastric ulcer
1PPIrabe,Barrett's esophagus
1PPIrabe,Zollinger-Ellison syndrome
1PPIrabe,"Connective tissue disease (e.g., lupus, scleroderma, crest),"
1PPIrabe,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)"
1PPIrabe,Other
ralox,"Clinical or radiographically-documented fracture due to osteoporosis - intolerable side effects to a minimum 1 month trial of oral bisphosphonates, alendronate or risedronate"
ralox,"Clinical or radiographically-documented fracture due to osteoporosis - unsatisfactory clinical response, defined as a new fragility fracture after 1 year adherence to alendronate or alendronate plus cholecalciferol or risedronate therapy"
ralox,Other
100extrabgts,"Not meeting glycemic targets, as determined by a physician, for 3 months or more"
100extrabgts,Acute illness or comorbidities that may impact blood glucose control
100extrabgts,"Changes in drug therapy that may impact blood glucose control (e.g., starting or stopping hypo- or hyperglycemic inducing medications, or drug-to-drug or drug-to-disease interactions)"
100extrabgts,"Occupations where hypoglycemia presents a significant safety risk (e.g., pilots, air traffic controllers, commercial drivers)"
100extrabgts,Gestational diabetes
100extrabgts,Other
omnipod,Type 1 Diabetes
omnipod,Other form of diabetes (please specify):
ypsoPump,Type 1 Diabetes
ypsoPump,Other form of diabetes (please specify):
miniMed,Type 1 Diabetes
miniMed,Other form of diabetes (please specify):
otherInsulinPumpNotApproved,nil
RBV,"non-submission ""form"""
rifaximin,Reducing the risk of overt hepatic encephalopathy (HE) recurrence - hospitalized with HE associated with cirrhosis of the live
rifaximin,Reducing the risk of overt hepatic encephalopathy (HE) recurrence - unable to achieve adequate control despite taking the maximum tolerated dose of lactulose
rifaximin,Other
risan,Plaque Psoriasis
risan,Other
Pagetsrise,diagnosis of Paget's disease
Pagetsrise,other
alenrise,Clinical or radiographically documented fracture due to osteoporosis
alenrise,Glucocorticoid-induced osteoporosis
alenrise,Other
Maintenarisp,For management of manifestations of schizophrenia
Maintenarisp,"For management of manifestations of related psychotic disorders (not dementia-related) - have tried oral aripiprazole, risperidone, or paliperidone PLUS at least one other antipsychotic agent AND continues to be inadequately controlled"
Maintenarisp,For management of manifestations of related psychotic disorders (not dementia-related) - are currently receiving a conventional depot antispychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia
Maintenarisp,For management of manifestations of related psychotic disorders (not dementia-related) - history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations
Maintenarisp,Other
ritux,Multiple Sclerosis
ritux,Rheumatoid Arthritis
ritux,Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
ritux,Other
DOACriva,Deep vein thrombosis (DVT)
DOACriva,Pulmonary embolism (PE)
DOACriva,Non-valvular atrial fibrillation
DOACriva,Other
cad,diagnosis of CAD and PAD
cad,Other
ADTIriva,"Initial - mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease"
ADTIriva,"Renewal -  mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease"
ADTIriva,Other
ropinirole,For the treatment of idiopathic Parkinson's disease - receiving treatment with levodopa and requires additional adjunctive therapy
ropinirole,For the treatment of idiopathic Parkinson's disease - cannot tolerate or has contraindications to levodopa
ropinirole,For the treatment of idiopathic Parkinson's disease - other
ropinirole,Other
rotig,"For the treatment of advanced stage Parkinson’s disease, when the patient is receiving treatment with levodopa AND requires additional adjunctive therapy"
rotig,Other
rufinamide,For the treatment of Lennox-Gastaut syndrome (LGS)
rufinamide,Other
Entresto,Patient has heart failure with New York Heart Association (NYHA) Class II to III symptoms - despite at least four weeks of treatment at the optimum stable dose of a beta-blocker and other recommended therapies
Entresto,Other
nebulessalb,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece
nebulessalb,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices
nebulessalb,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily
nebulessalb,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber.
nebulessalb,Other
LABAsalm,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid 
LABAsalm,Other
COPDsalm,Diagnosis of COPD with a post-bronchodilator FEV1/FVC < 0.70 AND contraindication or intolerance to a long-acting muscarinic receptor antagonist (LAMAs)
COPDsalm,Other
sarilumab,Rheumatoid Arthritis
sarilumab,Other
DPP4saxa,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea
DPP4saxa,Type 2 diabetes - Dual therapy of metformin and an insulin
DPP4saxa,Type 2 diabetes - trial of one agent
DPP4saxa,Other
secukinumab,Ankylosing Spondylitis
secukinumab,Psoriatic Arthritis
secukinumab,Plaque Psoriasis
secukinumab,Other
PAH5,Idiopathic pulmonary arterial hypertension (PAH)
PAH5,Heritable PAH
PAH5,PAH associated with connective tissue disorders
PAH5,PAH associated with congenital heart disease
PAH5,Adult patient with World Health Organization / New York Heart Association functional class III PAH whose symptoms are inadequately controlled with a phosphodiesterase-type 5 inhibitor and endothelin receptor antagonist:
PAH5,Other
semaglutide,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea
semaglutide,Type 2 diabetes - Dual therapy of metformin and an insulin
semaglutide,Type 2 diabetes - trial of one agent
semaglutide,Other
sildenafil,As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)
sildenafil,As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH)
sildenafil,Other
statinssimv,Results of trial to atorvastatin - Treatment failure
statinssimv,Results of trial to atorvastatin - Intolerance
statinssimv,Results of trial to atorvastatin - Other
statinssimv,Results of trial to rosuvastatin - Treatment failure
statinssimv,Results of trial to rosuvastatin - Intolerance
statinssimv,Results of trial to rosuvastatin - Other
statinssimv,Other
nebulescrom,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece
nebulescrom,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices
nebulescrom,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily
nebulescrom,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber.
nebulescrom,Other
sovaldi,genotype 2 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: (with RBV) for 12 weeks.
sovaldi,genotype 3 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: (with RBV) for 24 weeks.
solifen,Overactive Bladder Syndrome
solifen,Who have developed SEVERE intolerance to immediate-release oxybutynin requiring discontinuation of oxybutynin
somatropin,For true growth hormone deficiency 
somatropin,For chronic renal insufficiency
somatropin,Other
stiripen,Diagnosis of severe myoclonic epilepsy in infancy (Dravet syndrome) 
stiripen,Other
sulindac,Rheumatoid Arthritis
sulindac,Psoriatic Arthritis
sulindac,Ankylosing Spondylitis
sulindac,Gout
sulindac,Lupus
sulindac,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
sulindac,Other
sumatrip,Nausea and vomiting prevents swallowing oral preparations
sumatrip,Oral absorption is not practical.
sumatrip,Other
tacrotopical,Diagnosis of eczema - is refractory to three months of potent topical corticosteroid therapy
tacrotopical,Diagnosis of eczema - is intolerant to topical corticosteroid treatment
tacrotopical,Other
tadalafil,As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)
tadalafil,As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH)
tadalafil,Other
ARBtelm,Patient has experienced intractable cough
ARBtelm,Patient has experienced angioedema
ARBtelm,Other
Twynsta,Patient has experienced intractable cough or angioedema on an Angiotensin Converting Enzyme Inhibitor (ACE-I) AND is currently taking stable doses of both telmisartan and amlodipine
Twynsta,Other
tenofovir,Chronic Hepatitis B
tenofovir,Viral breakthrough while on treatment (lamivudine resistance)
tenofovir,Viral breakthrough while on treatment (adefovir experienced with persistant viremia and lamivudine resistance)
tenofovir,Other - patient is pregnant; to reduce vertical transmission of Hepatitis B
tenofovir,Other - Hepatitis B reactivation prophylaxis while on immunosuppressant(s)
tenofovir,Other
tenoxicam,Rheumatoid Arthritis
tenoxicam,Psoriatic Arthritis
tenoxicam,Ankylosing Spondylitis
tenoxicam,Gout
tenoxicam,Lupus
tenoxicam,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
tenoxicam,Other
terbinafine,Diagnosis of severe onychomycosis
terbinafine,Other
teriflunomide,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial
teriflunomide,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal
teriflunomide,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch
testosteronecypi,For the treatment of testosterone deficiency in - hypogonadism
testosteronecypi,For the treatment of testosterone deficiency in - orchiectomy
testosteronecypi,For the treatment of testosterone deficiency in - undescended testes
testosteronecypi,For the treatment of testosterone deficiency in - Klinefelter's syndrome
testosteronecypi,For the treatment of testosterone deficiency in - female-to-male transformation
testosteronecypi,For the treatment of testosterone deficiency in - pituitary tumour
testosteronecypi,For the treatment of testosterone deficiency in - removal of pituitary gland
testosteronecypi,For the indication of documented low testosterone levels due to - surgery of pituitary gland
testosteronecypi,For the indication of documented low testosterone levels due to - AIDS-wasting syndrome
testosteronecypi,Other
testosteroneenan,For the treatment of testosterone deficiency in - hypogonadism
testosteroneenan,For the treatment of testosterone deficiency in - orchiectomy
testosteroneenan,For the treatment of testosterone deficiency in - undescended testes
testosteroneenan,For the treatment of testosterone deficiency in - Klinefelter's syndrome
testosteroneenan,For the treatment of testosterone deficiency in - female-to-male transformation
testosteroneenan,For the treatment of testosterone deficiency in - pituitary tumour
testosteroneenan,For the treatment of testosterone deficiency in - removal of pituitary gland
testosteroneenan,For the indication of documented low testosterone levels due to - surgery of pituitary gland
testosteroneenan,For the indication of documented low testosterone levels due to - AIDS-wasting syndrome
testosteroneenan,Other
testosteroneprop,For the treatment of testosterone deficiency in - hypogonadism
testosteroneprop,For the treatment of testosterone deficiency in - orchiectomy
testosteroneprop,For the treatment of testosterone deficiency in - undescended testes
testosteroneprop,For the treatment of testosterone deficiency in - Klinefelter's syndrome
testosteroneprop,For the treatment of testosterone deficiency in - female-to-male transformation
testosteroneprop,For the treatment of testosterone deficiency in - pituitary tumour
testosteroneprop,For the treatment of testosterone deficiency in - removal of pituitary gland
testosteroneprop,For the indication of documented low testosterone levels due to - surgery of pituitary gland
testosteroneprop,For the indication of documented low testosterone levels due to - AIDS-wasting syndrome
testosteroneprop,Other
tiaprofenic,Rheumatoid Arthritis
tiaprofenic,Psoriatic Arthritis
tiaprofenic,Ankylosing Spondylitis
tiaprofenic,Diagnosis of gout
tiaprofenic,Lupus
tiaprofenic,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam"
tiaprofenic,Other
ticag,Definite stent thrombosis after revascularization with percutaneous coronary intervention (PCI)
ticag,Recurrent ST or non-ST elevation myocardial infarction (STEMI or NSTEMI) after revascularization with percutaneous coronary intervention (PCI)
ticag,Recurrent unstable angina after revascularization with percutaneous coronary intervention (PCI)
ticag,Undergoing revascularization via percutaneous coronary intervention (PCI) secondary to ST or non-ST elevation myocardial infarction (STEMI or NSTEMI) or unstable angina
ticag,Other
ticlo,"Secondary prevention of coronary, cerebral and peripheral vascular occlusion and embolization - treatment failure with ASA"
ticlo,"Secondary prevention of coronary, cerebral and peripheral vascular occlusion and embolization - intolerance to ASA"
ticlo,Other
tinzaparin,Treatment of venous thromboembolism
tinzaparin,Treatment of venous thromboembolism associated with cancer
tinzaparin,Prophylaxis of venous thromboembolism
tinzaparin,Other
COPDtiop,Diagnosis of chronic obstructive pulmonary disease (COPD) AND failureof both tiotropium and umeclidinium
COPDtiop,Other
COPDtiopolod,Diagnosis of moderate to very severe COPD¹ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted AND inadequate response after minimum of 6 month trial of either LAMA or LABA
COPDtiopolod,Other
tizan,Diagnosis of spasticity - treatment failure with diazepam
tizan,Diagnosis of spasticity - intolerance to diazepam
tizan,Diagnosis of spasticity - treatment failure with baclofen
tizan,Diagnosis of spasticity - intolerance to baclofen
tizan,Other
tobi,Moderate to severe cystic fibrosis
tobi,Chronic pulmonary Pseudomonas aeruginosa infections
tobi,Does not tolerate injectable forms of tobramycin to manage inhalation issues
tobi,Other
tociliz,Rheumatoid Arthritis
tociliz,Giant Cell Arteritis (GCA)
tociliz,Polyarticular Juvenile Idiopathic Arthritis (pJIA)
tociliz,Systemic Juvenile Idiopathic Arthritis (sJIA)
tociliz,Other
tofacitinib,Rheumatoid Arthritis
tofacitinib,Ulcerative Colitis
tofacitinib,Other
ACEItran,"Treatment failure on optimal doses of, or intolerance to, ramipril"
ACEItran,Requiring medication(s) for co-existing chronic condition(s)
ACEItran,Other
PAH4,For the treatment of functional class IV pulmonary arterial hypertension (PAH) - inadequate response to the non-prostanoid therapies
PAH4,For the treatment of functional class IV pulmonary arterial hypertension (PAH) - contraindication to the non-prostanoid therapies
PAH4,Other
tretinoin,Diagnosis of acne
tretinoin,Diagnosis of skin cancer
tretinoin,Other
COPDumecvila,Diagnosis of moderate to very severe COPD¹ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted AND inadequate response after minimum of 6 month trial of either LAMA or LABA
COPDumecvila,Other
uste,Plaque Psoriasis
uste,Other
valganciclovir,"For the prophylaxis of cytomegalovirus (CMV) infection post stem cell transplant, in patients who test positive for CMV upon polymerase chain reaction (PCR) laboratory testing."
valganciclovir,Other
ARBvals,Patient has experienced intractable cough
ARBvals,Patient has experienced angioedema
ARBvals,Other
vancomycin,"Treatment of symptomatic Clostridium Difficile Infection (CDI) - intolerant or cannot take metronidazole (e.g., pregnant women, alcoholism)"
vancomycin,Treatment of symptomatic Clostridium Difficile Infection (CDI) - failed to respond to 4-6 days of oral metronidazole 500mg three times daily
vancomycin,symptomatic C. Difficile Infection (CDI) - symptoms of moderate to severe disease OR is experiencing a second disease recurrence (within 2-8 weeks of diagnosis of a previous episode)
vancomycin,"symptomatic C. Difficile Infection (CDI) - initiated on vancomycin as an inpatient (e.g. in a hospital setting, nursing home, or long-term care facility) and requires continuation"
vancomycin,Other
vedoIV,Moderate to Severe Active Crohn's
vedoIV,Fistulizing Crohn's
vedoIV,Ulcerative Colitis
epclusa,Genotype 1 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,Genotype 1 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Genotype 2 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,Genotype 2 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Genotype 3 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,Genptype 3 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Genotype 4 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,Genotype 4 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Genotype 5 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,Genotype 5 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Genotype 6 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,Genotype 6 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,Mixed genotype - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.
epclusa,Mixed genotype - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.
epclusa,liver transplant recipient
epclusa,lung transplant recipient
vosevi,Genotype 1 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 1 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 2 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 2 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 3 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 3 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,"Genotype 3 - Exceptional Request: treatment naïve, F4 cirrhosis"
vosevi,Genotype 4 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 4 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Genotype 5 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks
vosevi,Genotype 6 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks
vosevi,Unable to verify genotype - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
vosevi,Unable to verify genotype - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.
voriconazole,For continuation of hospital-initiated treatment of invasive aspergillosis
voriconazole,For continuation of hospital-initiated treatment of culture proven invasive candidiasis with documented resistance to fluconazole
voriconazole,Other
zip,Diagnosis of schizophrenia 
zip,Other psychosis (not dementia related)
zip,Other
denosacla,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - immune-mediated hypersensitivity reaction to oral bisphosphonates
denosacla,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia
denosacla,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - other
denosacla,Other
zopiclone,For the treatment of insomnia - HIV/AIDS
zopiclone,For the treatment of insomnia - identified psychiatric diagnosis
zopiclone,"For the treatment of insomnia - intolerant to, or failed on, at least three specified benzodiazepines"
zopiclone,"For the treatment of insomnia - intolerant to, or failed on, at least two specified benzodiazepines and one other specified hypnotic agent"
zopiclone,For the treatment of insomnia - history of drug or alcohol addiction
zopiclone,"For the treatment of insomnia - fragile, elderly patient"
zopiclone,Other
